A detailed history of Bayforest Capital LTD transactions in Alkermes Plc. stock. As of the latest transaction made, Bayforest Capital LTD holds 9,270 shares of ALKS stock, worth $283,754. This represents 0.14% of its overall portfolio holdings.

Number of Shares
9,270
Previous 4,518 105.18%
Holding current value
$283,754
Previous $130 Million 26.35%
% of portfolio
0.14%
Previous 0.16%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 08, 2025

BUY
$28.08 - $36.0 $133,436 - $171,072
4,752 Added 105.18%
9,270 $164 Million
Q4 2024

Feb 14, 2025

BUY
$25.7 - $31.46 $116,112 - $142,136
4,518 New
4,518 $130 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $5.03B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Bayforest Capital LTD Portfolio

Follow Bayforest Capital LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayforest Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Bayforest Capital LTD with notifications on news.